Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial by Luvira, V, Schilling, WHK, Jittamala, P, Watson, JA, Boyd, S, Siripoon, T, Ngamprasertchai, T, Almeida, PJ, Ekkapongpisit, M, Cruz, C, Callery, JJ, Singh, S, Tuntipaiboontana, R, Kruabkontho, V, Ngernseng, T, Tubprasert, J, Abdad, MY, Keayarsa, S, Madmanee, W, Aguiar, RS, Santos, FM, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Poovorawan, K, Imwong, M, Taylor, WRJ, Chotivanich, V, Chotivanich, K, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ

Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV) by Schilling, WHK, Jittamala, P, Watson, JA, Ekkapongpisit, M, Siripoon, T, Ngamprasertchai, T, Luvira, V, Pongwilai, S, Cruz, CV, Callery, JJ, Boyd, S, Kruabkontho, V, Ngernseng, T, Tubprasert, J, Abdad, MY, Piaraksa, N, Suwannasin, K, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Sookprome, S, Poovorawan, K, Thaipadungpanit, J, Blacksell, S, Imwong, M, Tarning, J, Taylor, WRJ, Chotivanich, V, Sangketchon, C, Ruksakul, W, Chotivanich, K, Teixeira, MM, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Piyaphanee, W, Phumratanaprapin, W, White, NJ

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adap... by Schilling, WHK, Jittamala, P, Watson, JA, Boyd, S, Luvira, V, Siripoon, T, Ngamprasertchai, T, Batty, EM, Cruz, C, Callery, JJ, Singh, S, Saroj, M, Kruabkontho, V, Ngernseng, T, Tanglakmankhong, N, Tubprasert, J, Abdad, MY, Madmanee, W, Kouhathong, J, Suwannasin, K, Pagornrat, W, Piaraksa, N, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Poovorawan, K, Potaporn, M, Srisubat, A, Loharjun, B, Taylor, WRJ, Chotivanich, V, Chotivanich, K, Imwong, M, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ

Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV) by Jittamala, P, Schilling, WHK, Watson, JA, Luvira, V, Siripoon, T, Ngamprasertchai, T, Almeida, PJ, Ekkapongpisit, M, Cruz, C, Callery, JJ, Boyd, S, Anunsittichai, O, Hongsuwan, M, Singhaboot, Y, Pagornrat, W, Tuntipaiboontana, R, Kruabkontho, V, Ngernseng, T, Tubprasert, J, Abdad, MY, Keayarsa, S, Madmanee, W, Aguiar, RS, Santos, FM, Batty, EM, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Sookprome, S, Poovorawan, K, Imwong, M, Taylor, WRJ, Chotivanich, V, Sangketchon, C, Ruksakul, W, Chotivanich, K, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ